The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P

Open source

DOI
10.1038/s41598-021-92774-z
Published
2021 Jul 2
Container
Scientific reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-021-92774-z,
  title = {The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.},
  author = {Pizzuti L and Barba M and Mazzotta M and Krasniqi E and Maugeri-Saccà M and Gamucci T and Berardi R and Livi L and Ficorella C and Natoli C and Cortesi E and Generali D and La Verde N and Cassano A and Bria E and Moscetti L and Michelotti A and Adamo V and Zamagni C and Tonini G and Sergi D and Marinelli D and Paoletti G and Tomao S and Botticelli A and Marchetti P and Tinari N and Grassadonia A and Valerio MR and Mirabelli R and Fabbri MA and D'Ostilio N and Veltri E and Corsi D and Garrone O and Paris I and Sarobba G and Meattini I and Pistelli M and Giotta F and Lorusso V and Garufi C and Russo A and Cazzaniga M and Del Medico P and Roselli M and Vaccaro A and Perracchio L and di Benedetto A and Daralioti T and Sperduti I and De Maria R and Di Leo A and Sanguineti G and Ciliberto G and Vici P},
  year = {2021},
  journal = {Scientific reports},
  doi = {10.1038/s41598-021-92774-z},
  url = {https://doi.org/10.1038/s41598-021-92774-z}
}

RIS

TY  - JOUR
TI  - The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
AU  - Pizzuti L
AU  - Barba M
AU  - Mazzotta M
AU  - Krasniqi E
AU  - Maugeri-Saccà M
AU  - Gamucci T
AU  - Berardi R
AU  - Livi L
AU  - Ficorella C
AU  - Natoli C
AU  - Cortesi E
AU  - Generali D
AU  - La Verde N
AU  - Cassano A
AU  - Bria E
AU  - Moscetti L
AU  - Michelotti A
AU  - Adamo V
AU  - Zamagni C
AU  - Tonini G
AU  - Sergi D
AU  - Marinelli D
AU  - Paoletti G
AU  - Tomao S
AU  - Botticelli A
AU  - Marchetti P
AU  - Tinari N
AU  - Grassadonia A
AU  - Valerio MR
AU  - Mirabelli R
AU  - Fabbri MA
AU  - D'Ostilio N
AU  - Veltri E
AU  - Corsi D
AU  - Garrone O
AU  - Paris I
AU  - Sarobba G
AU  - Meattini I
AU  - Pistelli M
AU  - Giotta F
AU  - Lorusso V
AU  - Garufi C
AU  - Russo A
AU  - Cazzaniga M
AU  - Del Medico P
AU  - Roselli M
AU  - Vaccaro A
AU  - Perracchio L
AU  - di Benedetto A
AU  - Daralioti T
AU  - Sperduti I
AU  - De Maria R
AU  - Di Leo A
AU  - Sanguineti G
AU  - Ciliberto G
AU  - Vici P
PY  - 2021
JO  - Scientific reports
DO  - 10.1038/s41598-021-92774-z
UR  - https://doi.org/10.1038/s41598-021-92774-z
ER  -

APA

L, P., M, B., M, M., E, K., M, M., T, G., R, B., L, L., C, F., C, N., E, C., D, G., N, L. V., A, C., E, B., L, M., A, M., V, A., C, Z., G, T., D, S., D, M., G, P., S, T., A, B., P, M., N, T., A, G., MR, V., R, M., MA, F., N, D., E, V., D, C., O, G., I, P., G, S., I, M., M, P., F, G., V, L., C, G., A, R., M, C., P, D. M., M, R., A, V., L, P., A, D. B., T, D., I, S., R, D. M., A, D. L., G, S., G, C., & P, V. (2021). The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.. Scientific reports. https://doi.org/10.1038/s41598-021-92774-z

Source records